Results 51 to 60 of about 20,522 (204)
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest +3 more
wiley +1 more source
Effect of ezetimibe on blood lipids.
Semi-fasted blood lipid levels of obese hyperlipidemic hamsters treated for 14 days with vehicle (PO, QD) or Ezetimibe (10.0 mg/kg, PO, QD).
Louise S. Dalbøge (420563) +6 more
core +1 more source
Cryo-EM structures of NPC1L1 reveal mechanisms of cholesterol transport and ezetimibe inhibition
The intestinal absorption of cholesterol is mediated by a multipass membrane protein, Niemann-Pick C1-Like 1 (NPC1L1), the molecular target of a cholesterol lowering therapy ezetimibe. While ezetimibe gained Food and Drug Administration approval in 2002,
Huang, Ching-Shin +9 more
core +1 more source
A cholesterol‐biomimetic AIE probe, TPAS‐PyCHO+, was designed and synthesized for selective imaging of nonalcoholic fatty liver. The probe hijacked NPC1L1‐mediated clathrin‐dependent endocytosis in steatotic hepatocytes, selectively accumulated in lipid droplets, and enabled high signal‐to‐noise ratio imaging of NAFLD in mice.
Kunyi Wang +7 more
wiley +1 more source
Niacin or Ezetimibe for Patients with, or at Risk of Coronary Heart Disease
Coronary heart disease treatment with HMG-CoA reductase inhibitors has been very successful. There is increasing interest in adding other lipid lowering therapy, primarily as additional therapy onto HMG-CoA reductase therapy.
Robert Guthrie
core +1 more source
EZETIMIBE IN HYPERCHOLESTEROLAEMIA
SUMMARYEzetimibe is the first member of a new class of selective cholesterol absorption inhibitors, compounds that effectively block intestinal absorption of dietary and biliary cholesterol, without affecting absorption of fat soluble vitamins or triglycerides.
openaire +2 more sources
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu +7 more
wiley +1 more source
Ezetimibe inhibits expression of acid sphingomyelinase in liver and intestine
Ezetimibe inhibits cholesterol absorption in the intestine. Sphingomyelin has strong interactions with cholesterol. We investigated the effects of ezetimibe on Sphingomyelinase (SMase) expression in intestine and liver. After feeding rats with ezetimibe (
Wu, Jun +19 more
core +1 more source
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus +7 more
wiley +1 more source
Efficient and scalable process for the synthesis of antihypercholesterolemic drug ezetimibe
An efficient and scalable process for the synthesis of antihypercholesterolemic drug ezetimibe through chiral Evans auxiliary (S)-4-phenyl-2-oxazolidinone is described.
Yijun Zhu (2975739) +5 more
core +1 more source

